Literature DB >> 23653251

Clinical and molecular characterization of McArdle's disease in Brazilian patients.

Juliana Gurgel-Giannetti1, Gisela Nogales-Gadea, Hélio van der Linden, Túlio Marcus Ribeiro Bellard, Geraldo Brasileiro Filho, Alexandre Varella Giannetti, Eralda Luiza de Castro Concentino, Mariz Vainzof.   

Abstract

McArdle's disease, a glycogen storage disease type V, is caused by a deficiency of the enzyme myophosphorylase, encoded by the PYGM gene. Worldwide distribution of mutations has revealed interesting data about the prevalence of mutations and population migrations. Currently, more than 100 mutations in the PYGM gene have been described, with some recurrent mutations in the different populations. However, no molecular studies of McArdle's disease were reported in Brazilian patients. Here, we describe the clinical phenotype and genotype of 10 patients from 8 unrelated Brazilian families. Among the 10 patients (3 females, 7 males), eight presented with the typical phenotype, with exercise intolerance, cramps, and myalgia; one patient showed permanent muscle weakness; and one patient showed a mild phenotype. Molecular analysis identified 5 different mutations in the 8 families, both in homozygosis or compound heterozygosis state. Four of them had already been described (p.R50X, p.T692kfs30, p.K609K, and p.G455R), and one, pI513V, is a novel heterozygous mutation. The common nonsense p.R50X mutation was found in 6 of the 8 families, being therefore the commonest mutation in the Brazilian population as well. Other mutations previously reported in European patients were also found in the patients in this study, which was expected considering the European ancestry of the Brazilian population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23653251     DOI: 10.1007/s12017-013-8233-2

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  13 in total

Review 1.  Pitfalls in electrodiagnosis.

Authors:  C Krarup
Journal:  J Neurol       Date:  1999-12       Impact factor: 4.849

2.  Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Identification of 20 novel mutations.

Authors:  Irene Vieitez; Susana Teijeira; Jose M Fernandez; Beatriz San Millan; Sara Miranda; Saida Ortolano; Sarah Louis; Pascal Laforet; Carmen Navarro
Journal:  Neuromuscul Disord       Date:  2011-07-29       Impact factor: 4.296

3.  Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations.

Authors:  M Deschauer; A Morgenroth; P R Joshi; D Gläser; P F Chinnery; J Aasly; H Schreiber; M Knape; S Zierz; M Vorgerd
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

4.  Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study.

Authors:  M A Martín; J C Rubio; J Buchbinder; R Fernández-Hojas; P del Hoyo; S Teijeira; J Gámez; C Navarro; J M Fernández; A Cabello; Y Campos; C Cervera; J M Culebras; A L Andreu; R Fletterick; J Arenas
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

5.  Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry.

Authors:  Alejandro Lucia; Jonatan R Ruiz; Alfredo Santalla; Gisela Nogales-Gadea; Juan C Rubio; Inés García-Consuegra; Ana Cabello; Margarita Pérez; Susana Teijeira; Irene Vieitez; Carmen Navarro; Joaquín Arenas; Miguel A Martin; Antoni L Andreu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-16       Impact factor: 10.154

6.  One-year follow-up in a child with McArdle disease: exercise is medicine.

Authors:  Margarita Pérez; Carl Foster; Marta González-Freire; Joaquín Arenas; Alejandro Lucia
Journal:  Pediatr Neurol       Date:  2008-02       Impact factor: 3.372

7.  A new rare mutation (691delCC/insAAA) in exon 17 of the PYGM gene causing McArdle disease.

Authors:  Beatriz Quintans; Amalia Sanchez-Andrade; Susana Teijeira; Roberto Fernandez-Hojas; Eloy Rivas; María José López; Carmen Navarro
Journal:  Arch Neurol       Date:  2004-07

8.  Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease.

Authors:  I Fernandez-Cadenas; A L Andreu; J Gamez; R Gonzalo; M A Martín; J C Rubio; J Arenas
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

Review 9.  McArdle disease: molecular genetic update.

Authors:  A L Andreu; G Nogales-Gadea; D Cassandrini; J Arenas; C Bruno
Journal:  Acta Myol       Date:  2007-07

10.  The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected.

Authors:  Sérgio D J Pena; Giuliano Di Pietro; Mateus Fuchshuber-Moraes; Julia Pasqualini Genro; Mara H Hutz; Fernanda de Souza Gomes Kehdy; Fabiana Kohlrausch; Luiz Alexandre Viana Magno; Raquel Carvalho Montenegro; Manoel Odorico Moraes; Maria Elisabete Amaral de Moraes; Milene Raiol de Moraes; Elida B Ojopi; Jamila A Perini; Clarice Racciopi; Andrea Kely Campos Ribeiro-Dos-Santos; Fabrício Rios-Santos; Marco A Romano-Silva; Vinicius A Sortica; Guilherme Suarez-Kurtz
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

View more
  6 in total

1.  The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications.

Authors:  Gisela Nogales-Gadea; Alfredo Santalla; Astrid Brull; Noemi de Luna; Alejandro Lucia; Tomàs Pinós
Journal:  J Inherit Metab Dis       Date:  2014-07-23       Impact factor: 4.982

2.  Absence of p.R50X Pygm read-through in McArdle disease cellular models.

Authors:  Guillermo Tarrasó; Alberto Real-Martinez; Marta Parés; Lídia Romero-Cortadellas; Laura Puigros; Laura Moya; Noemí de Luna; Astrid Brull; Miguel Angel Martín; Joaquin Arenas; Alejandro Lucia; Antoni L Andreu; Jordi Barquinero; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Dis Model Mech       Date:  2020-01-13       Impact factor: 5.758

3.  PYGM mRNA expression in McArdle disease: Demographic, clinical, morphological and genetic features.

Authors:  Alzira A S Carvalho; Denise M Christofolini; Matheus M Perez; Beatriz C A Alves; Itatiana Rodart; Francisco W S Figueiredo; Karine C Turke; David Feder; Marcondes C F Junior; Ana M Nucci; Fernando L A Fonseca
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

4.  Quantitative proteomics analysis to identify biomarkers of chronic myofascial pain and therapeutic targets of dry needling in a rat model of myofascial trigger points.

Authors:  Li-Hui Li; Qiang-Min Huang; Marco Barbero; Lin Liu; Thi-Tham Nguyen; Matteo Beretta-Piccoli; An-Le Xu; Li-Juan Ji
Journal:  J Pain Res       Date:  2019-01-07       Impact factor: 3.133

5.  Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry).

Authors:  Tomàs Pinós; Antoni L Andreu; Claudio Bruno; Georgios M Hadjigeorgiou; Ronald G Haller; Pascal Laforêt; Alejandro Lucía; Miguel A Martín; Andrea Martinuzzi; Carmen Navarro; Piraye Oflazer; Jean Pouget; Ros Quinlivan; Sabrina Sacconi; Renata S Scalco; Antonio Toscano; John Vissing; Matthias Vorgerd; Andrew Wakelin; Ramon Martí
Journal:  Orphanet J Rare Dis       Date:  2020-10-15       Impact factor: 4.123

Review 6.  Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies.

Authors:  Mónica Villarreal-Salazar; Astrid Brull; Gisela Nogales-Gadea; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alfredo Santalla; Alejandro Lucia; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.